

REMARKS

Restriction to one of the following groups of claims has been required under 35 U.S.C. § 121:

- I. Claims 1-8, drawn to a transgenic non-human mammal comprising a polynucleotide encoding a soluble marker protein functionally linked to a regulatory sequence of an endogenous E-selectin, classified in class 800, subclass 13.
- II. Claims 1-6, drawn to a somatic recombinant non-human mammal comprising a polynucleotide encoding a soluble marker protein functionally linked to a regulatory sequence or an endogenous E-selectin, classified in class 800, subclass 13.
- III. Claims 9-12, drawn to a knockout mouse homozygous or heterozygous for an E-selectin allele comprising a polynucleotide encoding a soluble marker transgene, classified in class 800, subclass 13.
- IV. Claim 13, drawn to a DNA sequence as identified by SEQ ID NO:9, classified in class 536, subclass 23.1.
- V. Claim 13, drawn to a DNA sequence as identified by SEQ ID NO:10, classified in class 536, subclass 23.1.
- VI. Claims 14 and 15, drawn to a method of screening using a transgenic animal of group I or II, classified in class 800, and subclass 21.
- VII. Claim 16, drawn to a modulator of E-selectin expression, classification to be determined depending on the nature of the modulator.
- VIII. Claim 17, drawn to a method of treating a patient using a modulator of group VII, classified in class 536, subclass 23.1.
- IX. Claim 18, drawn to a method of monitoring progression of a disease, comprising breeding or a transgenic animal and a disease model animal, classified in class 800, subclass 21.


Applicants hereby elect without traverse Group I, i.e., claims 1-8, drawn to a transgenic non-human mammal comprising a polynucleotide encoding a soluble marker protein functionally linked to a regulatory sequence of an endogenous E-selectin, for continued prosecution in this application. Applicants reserve the right to file one or more divisional applications directed to the subject matter of the non-elected claims.

Due to the possibility of rejoinder, the non-elected claims have not been cancelled from this application.

Early action on the merits is respectfully requested.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7909



Ann R. Pokalsky
Attorney for Applicants
Reg. No. 34,697

Date: June 23, 2006